Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC)
US11986526B2 · kind B2 · utility
0Cited by
94References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 19, 2020 |
| Grant date | May 21, 2024 |
| Priority date | — |
| Expiry date | Jan 11, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.